Corcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call

Corcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host 
Conference Call 
MENLO PARK, CA -- (Marketwired) -- 11/04/13 --  Corcept Therapeutics
Incorporated (NASDAQ: CORT) today announced it will report third
quarter 2013 financial results on November 7, 2013. The Company will
host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time).  
Conference Call Information 
To participate, dial 1-888-771-4371 from the United States or
+1-847-585-4405 internationally approximately 10 minutes before the
start of the call. The passcode is 35967600.  
A replay will be available through November 21, 2013 at
1-888-843-7419 from the United States and +1-630-652-3042
internationally. The passcode is 35967600.  
About Corcept Therapeutics Incorporated 
Corcept is a pharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of
severe metabolic and psychiatric disorders. Korlym, a first
generation competitive GR-II antagonist, is the company's first
FDA-approved medication. The company has a phase 3 trial underway for
mifepristone for treatment of the psychotic features of psychotic
depression and a portfolio of selective GR-II antagonists that
competitively block the effects of cortisol but not progesterone. It
owns extensive intellectual property covering the use of GR-II
antagonists, including mifepristone, in the treatment of a wide
variety of metabolic, psychiatric and other disorders. It also holds
composition of matter patents for its selective GR-II antagonists. 
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com